RecruitingPhase 1NCT07531095

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer

Sponsor

Amgen

Enrollment

160 participants

Start Date

Apr 21, 2026

Study Type

INTERVENTIONAL

Conditions

Small Cell Lung Cancer

Summary

The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Durvalumab, a drug called Tarlatamab, and others for people with small cell lung cancer. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZL-1310

ZL-1310 will be administered as an IV infusion.

DRUGTarlatamab

Tarlatamab will be administered as an IV infusion.

DRUGDurvalumab

Durvalumab will be administered as an IV infusion.

Locations(22)

City of Hope Cancer Center Phoenix

Goodyear, Arizona, United States

City of Hope Chicago

Zion, Illinois, United States

Health Partners Cancer Center at Regions Hospital

Saint Paul, Minnesota, United States

New York University Cancer Institute

New York, New York, United States

Baptist Cancer Center

Memphis, Tennessee, United States

Next Virginia

Fairfax, Virginia, United States

Universitair Ziekenhuis Gent

Ghent, Belgium

Ziekenhuis aan de Stroom Augustinus

Wilrijk, Belgium

Hopital de la Timone

Marseille, France

Gustave Roussy

Villejuif, France

Universitaetsklinikum Dresden

Dresden, Germany

Universitaetsklinikum Wuerzburg

Würzburg, Germany

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland

Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Gliwice, Poland

Hospital Clinico Universitario Virgen de la Victoria

Málaga, Andalusia, Spain

Hospital Universitari Vall d Hebron

Barcelona, Catalonia, Spain

Hospital Clinico Universitario de Valencia

Valencia, Valencia, Spain

Hospital Universitario Ramon y Cajal

Madrid, Spain

Kantonsspital Sankt Gallen

Sankt Gallen, Switzerland

Adana Sehir Egitim ve Arastirma Hastanesi

Adana, Turkey (Türkiye)

Hacettepe Universitesi Tip Fakultesi Hastanesi

Ankara, Turkey (Türkiye)

Izmir Ekonomi Universitesi Medical Point Hastanesi

Izmir, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07531095

Related Trials

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07365241

Tarlatamab for SCLC Brain Metastases

NCT074023434 locations

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT0747628721 locations

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT021461701 location

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT0715517461 locations